Accretion Pharmaceuticals Limited (NSE:ACCPL)

Accretion Pharmaceuticals Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	898.18	898.18	573.76	133.53	295.32	225.84
Revenue Growth	8.68%	56.54%	329.70%	-54.79%	30.76%	-
Gross Profit Gross Profit Growth	246.65	246.65	173.55	39.17	55.21	45.91
Operating Income Operating Income Growth	139.31	139.31	111.29	23.58	12.15	11.21
Net Income Net Income Growth	96.68	96.68	67.94	14.93	1.04	0.79
Earnings Per Share EPS Growth	9.03	9.03	8.48	1.96	-	-
EPS Growth	-8.07%	6.54%	332.43%	-	-	-

Revenue by Geography

Chart

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
India India Growth	526.12	123.81	293.33	222.92
outside India outside India Growth	47.64	9.72	-	-
Total Total Growth	573.76	133.53	293.84	222.92

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	40.21	40.21	0.51	0.92	0.36	3.75
Total Debt Total Debt Growth	123.21	123.21	141.04	134.78	84.66	76.08
Net Cash (Debt) Net Cash Growth	-83.01	-83.01	-140.53	-133.86	-84.29	-72.33
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-7.75	-7.75	-17.53	-17.61	-	-

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-146.21	-146.21	57.5	-115.09	3.21	21.5
Capital Expenditures CapEx Growth	-85.34	-85.34	-16.11	-54.78	-11.78	-2.57
Free Cash Flow Free Cash Flow Growth	-231.55	-231.55	41.39	-169.87	-8.57	18.93
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	27.46%	27.46%	30.25%	29.33%	18.70%	20.33%
Operating Margin	15.51%	15.51%	19.40%	17.66%	4.12%	4.96%
Pretax Margin	14.57%	14.57%	17.02%	14.94%	0.47%	0.46%
Profit Margin	10.76%	10.76%	11.84%	11.18%	0.35%	0.35%
FCF Margin	-25.78%	-25.78%	7.21%	-127.22%	-2.90%	8.38%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 3, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	18.82	7.31	-	-	-	-
PS Ratio	2.10	0.79	-	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 31, 2026

Data Sources Report a data error